The proposed bill, if enacted, would introduce new provisions to the Arizona Revised Statutes by appropriating $10 million from the state General Fund for fiscal year 2025-2026 to the Department of Health Services (DHS). This funding is designated for awarding grants aimed at clinical trials or research on midomafetamine as a treatment for post-traumatic stress disorder (PTSD). The bill specifies that grants can only be awarded to entities that have completed at least one late-stage clinical trial and are currently involved in the FDA drug review process for midomafetamine related to PTSD.

Additionally, the bill includes a provision that exempts this appropriation from the usual lapsing of funds as outlined in section 35-190 of the Arizona Revised Statutes. This means that the allocated funds would not expire at the end of the fiscal year, allowing for continued use in the specified research initiatives. Overall, the bill aims to enhance research efforts for PTSD treatment through targeted funding and regulatory exemptions.